INO-9012: Clinical Trials

7 trials of INO-9012, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 active not recruiting, 1 recruiting. 7 Phase 2, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Active not recruiting 2, Recruiting 1
Phase 16Completed 4, Active not recruiting 2

Follow INO-9012: new trials by email Literature Review of INO-9012 trials Research Report on INO-9012

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012 - HCC
Phase 2RecruitingGeneos Therapeutics902026-09-012026-09-23
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
GNOS-PV02, INO-9012, Pembrolizumab - HCC
Phase 1 / Phase 2Active not recruitingGeneos Therapeutics362020-03-012026-09-24
Therapeutic Vaccination in Treated HIV Disease
PENNVAX-GP, INO-6145, INO-9012 - HIV-1-infection
Phase 1 / Phase 2CompletedSteven Deeks562018-08-012023-05-31
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
INO-5401, INO-9012, Atezolizumab - Urothelial Carcinoma
Phase 1 / Phase 2CompletedInovio Pharmaceuticals352018-07-242026-09-02
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
INO-5401, INO-9012, Cemiplimab - Glioblastoma
Phase 1 / Phase 2Active not recruitingInovio Pharmaceuticals522018-05-312026-10-22
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
INO-3112, CELLECTRA™-5P - Head and Neck Squamous Cell Cancer
Phase 1 / Phase 2CompletedInovio Pharmaceuticals222014-08-132021-01-22
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
INO-3112, CELLECTRA™-5P - Cervical Cancer
Phase 1 / Phase 2CompletedInovio Pharmaceuticals102014-06-062021-02-21

Conditions studied

Carcinoma, Transitional Cell (1)  ·  Glioblastoma (1)  ·  Uterine Cervical Neoplasms (1)

Sponsors

Inovio Pharmaceuticals (4)  ·  Geneos Therapeutics (2)  ·  Steven Deeks (1)

Countries

United States (7)  ·  New Zealand (2)

Top investigators

Jeffrey Skolnik, MD (4)  ·  Steven Deeks, MD (1)

Results publications

PMID 38584166

NIH funding

U01AI131296 (1)